The Optimizing Prevention Technology Introduction on Schedule (OPTIONS) consortium is one of five interlinked projects funded by the U.S. Agency for International Development (USAID), in partnership with the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR), to expedite and sustain access to antiretroviral-based HIV prevention products. The consortium represents an international, multidisciplinary partnership that brings together a unique combination of global, regional and country experts across the antiretroviral (ARV) research-to-rollout continuum.
FHI 360 leads the consortium, which comprises two additional global HIV prevention research and advocacy core partners, Wits Reproductive Health and HIV Institute (Wits RHI) and AVAC. Their global and regional technical expertise is complemented by six primary partners who bring specialized technical knowledge and strong in-country capacity: Avenir Health, FSG, London School of Hygiene & Tropical Medicine, LVCT Health, McCann Global Health and Pangaea Zimbabwe AIDS Trust.
The consortium works to accelerate the introduction of new HIV prevention products by providing support and technical assistance for investment scenarios, market-shaping strategies, country-level support, implementation science and health systems strengthening. The goal of the consortium is to provide targeted support to expedite and sustain access to ARV-based HIV prevention products in countries and among populations where most needed.
OPTIONS works in sub-Saharan Africa with ministries of health, USAID missions, product developers, implementers, manufacturers, other USAID microbicide annual program statement (APS) grantees, donors, the Joint United Nations Programme on HIV/AIDS, the World Health Organization, research organizations and civil society organizations to ensure broad stakeholder engagement.
In April 2016, OPTIONS/AVAC developed a new section of PrEPWatch — a clearinghouse of information on PrEP science, research, cost, access and advocacy — focused on implementation efforts underway. Specifically, the USAID-Supported Initiatives page offers an overview of the five Microbicide Product Introduction Initiative (MPii) projects, and country pages for Kenya, South Africa and Zimbabwe give the full spectrum of product introduction work for oral PrEP, the dapivirine ring, and OPTIONS activities as applicable. PrEPWatch will continue to grow as PrEP introduction and rollout moves forward and as new efforts and initiatives are started by all MPii projects. For more information, please contact MPiiPrEPWatch@optionsconsortium.org. Follow OPTIONS on Twitter @optionsmpii.
The other four USAID projects working toward ARV-based HIV prevention rollout are EMOTION, POWER, CHARISMA and GEMS. FHI 360 is a partner on the CHARISMA and GEMS projects.
MPii Microbicide Stakeholder Update Resources
For more information and updates on the work being done under the MPii agreements, subscribe to the MPii e-blast.